NetworkNewsBreaks – Cerulean Pharma (NASDAQ: CERU) Shares Dive on Stock Purchase Agreement with Daré Bioscience
Shares of Cerulean Pharma (NASDAQ: CERU) dropped 60% this morning after the company said it entered a definitive stock purchase agreement with Daré Bioscience, Inc. under which the equityholders of Daré will become the majority owners of Cerulean. The transaction will result in a public, Nasdaq-listed company focused on the development and commercialization of products for women’s reproductive health. Daré’s product candidate, Ovaprene®, is a clinical stage, non-hormonal contraceptive ring for monthly use that potentially addresses a significant unmet need in the $16 billion global contraception market. The combined company will operate under the name Daré; its CEO will be…







